Clene Inc. to Share Corporate Update at Emerging Growth Conference

Clene Inc. (NASDAQ: CLNN), a clinical-stage biopharmaceutical company, is scheduled to present a corporate update at the Emerging Growth Conference on August 20, 2025. The presentation, which will take place at 2:20 p.m. ET, will be available via a live webcast through the Events section of Clene’s website and the conference registration link. Replays will be accessible through the conference portal and YouTube channel.

The company, focused on developing innovative treatments for neurodegenerative diseases such as ALS and MS, is at the forefront of research aimed at improving mitochondrial health and protecting neuronal function. Its investigational therapy, CNM-Au8®, represents a first-in-class approach targeting mitochondrial function and the NAD pathway to reduce oxidative stress and enhance cell survival in the central nervous system.

This presentation is significant for investors and the medical community as it provides insights into Clene's progress and future directions in addressing unmet medical needs in neurodegenerative diseases. The opportunity to engage with the company's leadership during the Q&A session offers a deeper understanding of its strategic priorities and the potential impact of its therapies.

For those interested in the latest developments from Clene Inc., additional information and updates are available in the company’s newsroom at https://ibn.fm/CLNN.